TOURETTE & SEPRANOLONE
COMMERCIAL POTENTIAL
150,000–200,000 treatable population
![Group 6 Group 6](https://asarinapharma.com/wp-content/uploads/elementor/thumbs/Group-6-ou533o6qkvquarsgm1ksytc80ekq89nrjg20f4t4wy.png)
TREATABLE CHILDREN IN US
A number of peer-reviewed articles(4) have confirmed that the prevalence of Tourette in the Western world is about 0.2 – 0.6%. This means that the treatable population in the US will be some 150,000-200,000.
PROFOUND CO-MORBIDITIES
Tourette co-occurs with other mental health or neurodevelopment conditions in over 80% of cases, typically including ASD (Autism Spectrum Disease); ADHD (Attention-Deficit Hyperactivity Disorder) and ADD (Attention Deficit Disorder). Mild SIB (self-injuring behavior) is also thought to affect up to 60% of Tourette patients. In reality therefore market penetration could be relatively low as Tourette patients may already be treated with both CBIT and pharmacological treatment.
![Mother and son making dough Mother and son are preparing dough for cookies together in the morning. Kid is throwing flour and is happy.](https://asarinapharma.com/wp-content/uploads/elementor/thumbs/iStock-1137073322-scaled-ou5342acy7ronff5ccr65bc37uwrrf8dy4krb1brd0.jpg)
Tourette prevalance
With Sepranolone treatment being efficacious but with none of the serious side effects of competitors, the US market potential is calculated to be approximately 150,000- 200,000 patients, at 35,000 – 52,000 USD per year. Factoring in that many patients may already be treated with CBIT and pharmacological treatment, the market penetration could realistically reach 10% of patients. Resultant peak sales would therefore be approximately 500 – 1,000 MUSD(5).